Voices

Aug 21, 2025, 11:40

FDA has Granted Full Market Approval for Papzimeos – NIH

The National Institutes of Health shared on LinkedIn:

“NIH is thrilled to announce that the FDA has granted full market approval for Papzimeos, a groundbreaking immunotherapy for adult patients with recurrent respiratory papillomatosis (RRP), a rare condition in which noncancerous growths develop in the air passages from the nose and mouth into the lungs.

This is the first-ever non-surgical treatment for this rare and debilitating disease. The achievement was made possible through the dedicated research of NIH investigators from the National Cancer Institute (NCI).

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Voices

OncoDaily

Voices

FDA has Granted Full Market Approval for Papzimeos – NIH